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Abstract
Over the past decade, knowledge of the genetic control
of human sex differentiation has greately expanded our
understanding of the developmental processes needed
to form a male or female. The purpose of this review is to
discuss how transcription factors are relevant to such
processes. Additionally, an attempt is made to relate cur-
rent knowledge of these factors with gender develop-
ment of subjects with intersex conditions. Finally, we dis-
cuss how information about the genetic control of sex
differentiation may contribute to decisions about medi-
cal treatment of individuals with conditions of abnormal
sex differentiation.
Copyright © 2000 S. Karger AG, Basel
Introduction
In our previous review of human sexual differentiation
[1] we succinctly presented the major physiological steps
involved. The first step, the genetic sex of the fertilized
egg, depends upon the chromosomal complement (23,X
or 23,Y) of the fertilizing sperm. This is followed by the
formation of undifferentiated structures that are common
to both sexes: two sets of undifferentiated sex ducts (mül-
lerian and wolffian duct systems), the gonadal ridge and
the external genitalia. In a third step, the testis determin-
ing factor (TDF) is responsible for testis determination. In
the absence of TDF, other factors permit ovarian forma-
tion.
The final classical steps in sexual differentiation are
based on testicular functions: the Sertoli cells of the testes
secrete müllerian inhibiting substance (MIS) that sup-
presses the development of female ducts. Simultaneously,
the Leydig cells of the testes secrete large amounts of tes-
tosterone that promote the growth of male ducts and mas-
culinizes the external genitalia. In contrast, the ovaries do
not secrete significant amounts of testosterone, resulting
in the disappearance of male ducts and lack of masculini-
zation of the external genitalia that remains female. Also,
the ovaries to not produce MIS early in fetal develop-
ment, which leads to development of female ducts. The
physiologic understanding of this fourth step in sexual dif-
ferentiation is a result of the contributions of Alfred Jost,
Nathalie Josso and colleagues.
In the past 10 years, it has been realized that the pheno-
typic formation of males and females is more complex
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than previously thought. This realization is due to pro-
gress in our understanding of the mechanisms involved in
controlling gene expression. Indeed, it is now clear that
the expression of many genes is tightly controlled by prod-
ucts termed transcription factors. Hence, in what follows,
we will summarize our current knowledge of these factors
as they relate to human sexual differentiation.
The Fertilized Egg
The first step in sex differentiation takes place at the
time of fertilization of the ovum by one sperm. Several
sperm attempt to reach the ovum, a few penetrate the
zona pellucidum surrounding the egg, but only one will
attach itself and fuse its acrosome (male pronucleus) to
the membrane of the egg. At this point, no other sperm
can fuse with the egg.
Later, the acrosome is included into the cytosol of the
egg, while the nucleus of the egg divides and eliminates
the second polar body. The female pronucleus joins with
that of the male, resulting in a diploid cell: the fertilized
egg.
At this point, the zygote includes 23 maternal chromo-
somes and 23 paternal chromosomes as well as maternal
mitochondrial DNA. This corresponds to approximately
3.5 billion base pairs of DNA that are organized into
100,000–150,000 genes. Each of these genes is transcribed
into a specific protein, and these proteins will organize
themselves into tissues, the tissues into organ systems and
these organs will form a woman or a man.
It is of interest to pause and reflect on the fact that
within this single fertilized egg, all of the necessary genetic
information is present for development of a multicellular
organism with specialized functional systems: the human
body. This is the result of a specific pattern of activation
of the various genes of the zygote. However, all genes are
not functional at the same time or with the same degree
of expression throughout development. The so-called
‘housekeeping’ genes are expressed all of the time, al-
though not always at the same level. These genes are
required for the overall maintenance and energy expendi-
ture of cells. Without them, a cell would not be viable.
Yet, it is evident that the energy requirements of a cell will
vary throughout its life cycle. As a result, the expression of
housekeeping genes is somewhat modulated to fit cellular
needs.
In contrast, genes with highly specialized functions
have expression patterns that are tightly modulated and
controlled by specific factors, the transcription factors.
Control of gene expression by transcription factors is
exerted in a temporal fashion that is unique to these
genes. Control is also exerted in a quantitative fashion, as
related to certain cellular needs.
Transcription Factors – Definition and
Classifications
Gene expression is regulated at several levels. It is con-
trolled first at the transcription level, followed by post-
transcriptional processing resulting in the formation of
mRNA. The next step is regulation of mRNA translation
with post-translational processing.
Transcription factors are trans-acting elements that
bind selectively to appropriate cis-acting DNA sequences
of the promoter of a gene. This interaction results in regu-
lation (up-regulation or down-regulation) of the rate of
gene transcription by the ‘transcription initiation com-
plex’. As already stated, transcription factors can act as
activators or repressors of gene transcription. If they work
in concert with other modulating elements, transcription
factors can be co-activators or co-repressors. Some tran-
scription factors act by changing the configuration of
DNA and are named architectural factors or high mobili-
ty group (HMG) proteins.
Transcription factors can be classified on the basis by
which they bind to DNA. DNA-binding domains include
homeodomains, zinc finger domains, basic leucine zipper
domains and basic helix-loop-helix domains [2].
Detection and Study of Transcription Factors
Involved in Sex Differentiation
It is often difficult to establish beyond doubt the role of
a protein that includes a DNA-binding domain. Detection
of genes involved in sex differentiation is accomplished
with chromosomal studies of patients presenting certain
phenotypes. For example, the locus of SRY was identified
by studying patients with XX sex reversal (a variant of
Klinefelter syndrome) and female infants with a 46,XY
complement (complete gonadal dysgenesis or Swyer syn-
drome).
An additional approach is the determination of the
timing of gene expression in sexual structures; the appear-
ance of a factor at a specific time in development of an
organ suggests that the factor plays a definite role in the
evolution of that organ. In ‘knock-out’ studies the result-
ing effects of suppression of a gene suggests the role of that
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gene. In vitro studies with expression vectors help to iden-
tify the effects of one gene product on the expression of
another gene. The combination of these techniques have
provided important information about the mechanisms
involved in human sex differentiation.
Transcription Factors Involved in Sex
Differentiation
Although our knowledge remains limited, a number of
transcription factors have been shown to play a role in
human sex differentiation. These include homeodomain
proteins like LIM1, zinc finger domain proteins like SF-1,
WT-1, DAX-1, the androgen receptor (AR) and HMG
proteins like SRY and SOX-9. Each of these factors has a
unique and specific action in the overall process of sex
differentiation; however, the absence of any one can result
in a similar phenotype of gonadal dysgenesis.
Homeodomain Proteins
The homeobox is a well-conserved 180 base pair region
of DNA that encodes for a 60-amino-acid motif. This
motif has a structure that includes 3 ·-helices with a ter-
minal arm. Homeodomain proteins contact DNA in a
major groove.
LIM1 Gene (Chromosome 11p12–13)
LIM1 is an example of a homeobox gene important to
sex differentiation. The LIM1 protein contains not only a
homeodomain, but it also has 2 zinc fingers comprised of
4 cysteines each. LIM1 has multiple roles in activating
and inhibiting many genes necessary to the general orga-
nization of various organ systems including those in-
volved in sex differentiation. In Lim1 knock-out mice, the
developmental result in an organism with no head, kid-
neys or gonads [3]. Homozygous deletions of Lim1 in
mice result in absence of kidneys, gonads and cranium.
This transcription factor is thought to organize other pro-
teins in the mesoderm, but the characterization of these
proteins is not known at this time due in part to the lethal-
ity of Lim1 mutations. The human LIM1 gene has been
identified [4]; however, mutations have yet to be re-
ported.
Nuclear Receptors
A second group of transcription factors important to
sex differentiation is the nuclear receptor superfamily,
consisting of a large number of proteins with a common
zinc finger element. Zinc fingers are formed by a zinc mol-
ecule attached to 4 molecules of cysteine (or 2 cysteines
and 2 histidines). Typically, nuclear receptors contain 3
domains: a DNA-binding domain represented by zinc fin-
gers, a ligand-binding domain and a transactivator or
modulator domain.
SF-1 Gene (Chromosome 9q33)
A nuclear receptor transcription factor associated with
sex differentiation is SF-1. The SF-1 protein contains the
3 typical domains mentioned above. However, because
the identity of the ligand is unknown at this time, SF-1 is
considered to be a member of the orphan nuclear receptor
family.
The first known role of SF-1 was that its protein is a
regulator of cytochrome P450 steroid hydroxylases impor-
tant to adrenal and gonadal steroid synthesis. SF-1 also
activates the ACTH receptor. A third role for SF-1 is acti-
vation of the expression of MIS [5]. The MIS and MIS
receptor II genes possess a specific sequence in their pro-
moter regions (AGGTCA) to which SF-1 can bind and
exert activating effects [6]. SF-1 can also synergize with
WT-1 to regulate MIS activity [7].
In studies of Sf-1 knock-out mice, gonadal develop-
ment stops at the early stage of the urogenital ridge.
Development of adrenals is also blocked in these animals
[5]. Furthermore, gonadotrope cell function of the anteri-
or pituitary is impaired in these animals, as is the ven-
tromedial hypothalamic region (VMH) that is an impor-
tant neural component for rodent lordosis and feeding
behavior [8].
Regardless of karyotype, both 46,XX and 46,XY Sf-1
knock-out mice fail to develop gonads or adrenal glands,
and exhibit female external genitalia and female duct
development along with male duct regression. A single
case of a human SF-1 mutation has been described. This
46,XY subject presented with female external genitalia,
müllerian duct development and adrenal failure [9].
In summary, SF-1 plays a major role in the early devel-
opment of the undifferentiated gonads, the anlage of the
adrenal glands, and areas in the central nervous system
necessary for secretion of gonadotropins and reproductive
behaviors in nonhuman animals. SF-1 regulates MIS
activity and it is necessary for steroid synthesis.
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WT-1 Gene (Chromosome 11p13)
A second nuclear receptor to be considered is the
Wilms’ tumor gene (WT-1). This gene encodes for a tran-
scription factor containing 2 zinc fingers [10, 11]. WT-1
binds to the DNA sequence CGCCCCCGC and is be-
lieved to act both as a transcriptional activator and repres-
sor [12].
Mutations of WT-1 result in Wilms’ tumors [13],
which are embryonic tumors of the kidney. In some cases,
the ‘WAGR phenomenon’ presents itself in subjects with
autosomal dominant WT-1 mutations. This phenomenon
includes the Wilms’ tumor, Aniridia, Gonadal dysgenesis,
and mental Retardation.
A second syndrome related to heterozygous WT-1 mu-
tations is Denys-Drash syndrome [14]. This syndrome is
characterized by kidney problems (of the Wilms’ tumor
type) and gonadal dysgenesis. Reduced WT-1 binding to
DNA has been identified in patients with Denys-Drash
syndrome [15]. Ambiguity of external genitalia occurs
only in 46,XY subjects, while 46,XX subjects have nor-
mal female external genitalia as expected from the work of
Jost.
A third syndrome known to be associated with WT-1
mutations is Frasier syndrome. This includes focal glo-
merular sclerosis of the kidneys in addition to gonadal
dysgenesis. In subjects with Frasier syndrome, an abnor-
mal splicing is thought to occur at intron 9 of the WT-1
gene [16].
Experiments with knock-out mice indicate that the
absence of Wt-1 is associated with normal early develop-
ment of the urogenital ridge, followed shortly thereafter
by a complete block in gonadal development [17]. In other
words, WT-1 appears to be important for maturation of
the urogenital ridge prior to differentiation of the bipoten-
tial gonad.
HMG Proteins
HMG protein transcription factors are also known as
DNA sequence-specific binding factors. These factors
bind to specific sequences of DNA, such as AACAAT and
AACAAAG. Because several sequence-specific binding
factors can bind to the same base pair series, HMG pro-
teins acquire individual specificity indirectly via other
cofactors.
HMG proteins bind to the minor groove in DNA and
result in a 60–85° bend at which point the DNA can
unwind and widen [18, 19]. This binding to DNA may act
to stabilize the binding of other proteins, or perhaps pro-
vide a binding site for specific activators. HMG proteins
involved in sex differentiation include products of the
SRY and SOX-9 genes. Both of these proteins are thought
to be necessary for the differentiation of the early, bipo-
tential gonad into a testis.
SRY Gene (Chromosome Yp 11.3)
The SRY gene produces an HMG protein that can
bend DNA [20], and is therefore referred to as an ‘archi-
tectural factor’. The SRY gene encodes a 204-amino-acid
protein. The HMG domain of this protein is comprised of
a highly conserved 79-amino-acid region [21].
It has been suggested that the specific role of SRY in
testis differentiation is to suppress genes involved in
female differentiation [22], or that it activates genes
necessary for male differentiation such as the MIS gene
[19, 23]. Knowledge pertaining to precise mechanisms
through which SRY triggers testis differentiation from an
undifferentiated gonad has not been established.
As previously noted, the mapping of deletions of the
Y chromosome in 46,XY females and additions to the
X chromosome in 46,XX males permitted the identifica-
tion of the sex-determining region Y (SRY) gene. The
importance of Sry for testis determination was confirmed
by injecting the gene in XX fertilized eggs of mice. The
result was offspring with testes and male genitalia [24].
What is known about SRY in humans is that mutations
of this gene can result in cases of complete gonadal dysgen-
esis among 46,XY individuals [19]. In complete gonadal
dysgenesis, development of the undifferentiated gonad
stops at an early stage. Sertoli cells do not develop, no MIS
is secreted and female ducts differentiate. Leydig cells are
absent resulting in a lack of production of testicular andro-
gens. In such conditions female genitalia develop and
wolffian ducts regress. In other words, individuals with
complete gonadal dysgenesis possess a 46,XY karyotype,
have female ducts and possess female external genitalia.
In most cases of complete gonadal dysgenesis with
SRY mutations, the majority of mutations occur within
the HMG box. However, only 10–15% of cases demon-
strate an SRY mutation. While SRY is necessary for testis
differentiation from a bipotential gonad, factors other
than SRY are also required [25].
SOX-9 Gene (Chromosome 17q-24.3–25.1)
A second HMG protein important to the process of tes-
tis differentiation is SOX-9. Like SRY, SOX-9 binds to
DNA at the base pair sequences AACAAT or AACAAAG
[26]. Specificity of SOX-9 is acquired through conjuga-
tion with cofactors.
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SOX-9 also binds to the DNA sequences ATGAAT
and CACAAT [27]. These sequences are involved with
chondrocyte-specific enhancers and type II collagen for-
mation. This explains why abnormalities of SOX-9 result
in abnormalities of both bone formation and sex differen-
tiation.
SOX-9 mutations in humans can result in a syndrome
known as campomelic dysplasia (CD), which is an autoso-
mal dominant trait [28, 29]. CD is characterized by a dis-
order of chondrocytes that results in multiple bone dys-
plasia. In 46,XY subjects affected by CD, approximately
75% exhibit abnormalities in sex differentiation ranging
from a normal-appearing female phenotype to an ambi-
guous one [30]. Phenotypic variation regarding abnormal
sex differentiation of subjects with SOX-9 mutations
probably relates to the penatrance of this mutation. It is of
interest that SOX-9 mutations resulting in gonadal abnor-
malities are associated with abnormalities of chondro-
cytes, whereas mutations resulting in chondrocyte abnor-
malities are not always associated with gonadal abnormal-
ities.
A possible mechanism of action of SOX-9 is that this
gene is regulated by SRY for the differentiation and long-
term maintenance of Sertoli cells. An additional, and not
mutually exclusive, role of SOX-9 may be suppression of
ovarian differentiation from an undifferentiated gonad
[22]. Finally, SOX-9 has been shown to interact with the
nuclear receptor SF-1 in regulating the MIS gene promot-
er [31].
Two Additional Nuclear Receptors
DAX-1 Gene (Chromosome Xp21)
DAX-1 is an atypical orphan nuclear receptor in that
the structure of this receptor does not include zinc fingers
in the DNA-binding domain. Instead, DAX-1 binds to
DNA via hairpin structures [32].
Results of DAX-1 mutations are similar to those de-
scribed for SF-1. Specifically, there is adrenal cortex
hypoplasia, hypogonadotropic hypogonadism and disrup-
tion to the ventromedial region of the hypothalamus [33,
34]. However, in contrast to SF-1, DAX-1 mutations do
not result in a total arrest of testicular or adrenal develop-
ment [35].
46,XY subjects with a duplication of the DAX-1 gene
exhibit partial gonadal dysgenesis, and 46,XY subjects
with DAX-1 deletions develop testes [36]. Additionally, a
46,XX subject with a homozygous DAX-1 mutation ex-
hibited ovarian development [37]. Therefore, DAX-1 is
considered to be a dosage sensitive ‘anti-testis’ factor as
opposed to a gene necessary for ovary differentiation [35,
38].
DAX-1 protein appears to be an important protein
transcription inhibitor. DAX-1 inhibits SF-1 transactiva-
tion [39] and also antagonizes the synergy that exists
between SF-1 and WT-1 [7]. DAX-1 inhibits activity of
the enzymes StAR [40], CYP11A and 3ß-hydroxysteroid
dehydrogenase [41]. These observations suggest that
DAX-1 acts as an SRY antagonist [35].
AR Gene (Chromosome Xq11–12)
The human AR gene is a single-copy gene comprised of
8 exons that encode for a protein consisting of 919 amino
acids [42, 43]. The ligand-binding domain of the AR pro-
tein binds to dihydrotestosterone (DHT) with very high
affinity and to testosterone with lower affinity. The AR-
DHT complex forms a homodimer that binds to a specific
DNA acceptor site to promote gene transcription [44].
The product of this activated gene transcription repre-
sents the androgen effect on the target cells.
The phenotype of 46,XY subjects and total absence of
AR expression is complete androgen insensitivity syn-
drome (CAIS). Individuals with CAIS exhibit normal
female external genitalia with a short vagina that ends
blindly. Two normally formed testes are present and are
undescended or found in the inguinal area. Women with
CAIS possess no müllerian ducts, and wolffian duct devel-
opment is usually absent or limited. At puberty, girls with
CAIS develop breasts, but exhibit sparse amounts of pub-
ic or axillary hair [45].
Multiple AR gene mutations have been identified,
with the majority occurring in exons 2 through 8, although
a few have been identified in exon 1. These mutations [see
website www.mcgil.ca/androgendb] result in either a com-
plete or partial form of AIS.
A Scheme for the Role of Presently Known
Transcription Factors Involved in Sex
Differentiation
Although our knowledge remains limited, an attempt
can be made to integrate the roles played by transcription
factors involved in sex differentiation (fig. 1). It appears
that LIM1 is involved in the formation of the urogenital
ridge early in embryonic development [3]. Next, the
effects of SF-1 and WT-1 are necessary to develop the
ridge into a bipotential gonad [5, 9, 17]. Thereafter the
SRY protein, along with SF-1, WT-1 and SOX-9 is
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Fig. 1. A scheme for the role of presently known transcription factors
involved in human sex differentiation. LIM1 most likely plays a role
in formation of the urogenital ridge. SF-1 and WT-1 are necessary for
the development of the bipotential gonad. SRY is needed to differen-
tiate the gonad into a testis, with the help of SOX-9, SF-1 and WT-1.
In the absence of SRY-DAX-1 appears to counteract the effects of
SF-1, SOX-9 and WT-1, leading to development of an ovary.
Fig. 2. Expression of the MIS gene is modulated by many transcrip-
tion factors. The WT-1 protein in collaboration with SOX-9 exert a
strong positive effect on the MIS gene promoter. SRY protein also
exerts a positive effect on the MIS gene by potentiating the expres-
sion of the SF-1 gene. This collection of positive transcription factors
overrides the negative effect of DAX-1 on the MIS promoter. The
result is early transcription of the MIS gene, leading to suppression of
müllerian duct development in a 46,XY fetus.
needed to differentiate the gonad into a testis, including
Sertoli cells that produce MIS and Leydig cells that secrete
testosterone [24]. This is possible in the presence of a sin-
gle dose of DAX-1, as duplication of this gene results in
ambiguous genitalia in a 46,XY subject [35, 38].
In a 46,XY embryo, the absence of SRY permits full
expression of genes that allow for the differentiation of an
ovary.
A Theoretical Outline of the Interactions of
Transcription Factors
On the basis of various studies, it is possible to con-
struct a system of the control of expression of the MIS
gene. The SRY protein may potentiate the expression of
the SF-1 gene [19]. Then, the SF-1 protein, in collabora-
tion with the SOX-9 protein, exerts a strong positive effect
on the expression of the MIS gene [31]. WT-1 also appears
to contribute a positive effect on the MIS gene [7]. The
combined positive action of SF-1, SOX-9 and WT-1
oppose the negative effect of DAX-1. The result is early
expression of the MIS gene with consequent suppression
of müllerian duct development (fig. 2).
In contrast, the absence of the SRY protein results in a
lack (or decrease) of a positive effect of SF-1 on MIS gene
activity [19, 23]. Under such conditions the negative
action of DAX-1 is prominent, and the MIS protein
appears later and/or in smaller amounts. This leads to
development of müllerian structures (fig. 3).
Clearly, the above speculations may not be entirely
accurate. This scheme, however, illustrates the fine moni-
toring exerted by transcription factors on the expression
of genes, such as the MIS gene, important to sex differen-
tiation.
It is also important to emphasize that several addition-
al transcription factors are likely involved in human sex
differentiation. For example, there is a series of SOX
genes (SRY-related homeobox genes) that could play a
role in sex differentiation such as SOX-3 [25]. Additional-
ly, a haplo-deletion of distal 9p chromosomal material
(genes DMRT1 and DMRT2) results in 46,XY subjects
with variable degrees of gonadal dysgenesis [46–48].
Transcription Factors and Human Behavior
Sex differences in human behaviors are well docu-
mented, and to a lesser extent sex differences in human
CNS structures have been identified [49]. However, it is
unclear how these dimorphic structures relate to behav-
iors such as gender identity/role (GI/R) and sexual orien-
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Fig. 3. In the absence of SRY, the positive effect of SF-1 on MIS gene
expression is greatly decreased. Under such conditions, the negative
effect of DAX-1 predominates and results in absent (and/or late)
expression of the MIS gene. This permits development of müllerian
ducts in a 46,XX fetus.
tation. Even if direct associations can be established
between sexually-dimorphic brain structures and behav-
iors, it remains difficult to identify a causal relationship
between the two.
Transcription factors are essential to the physiologic
processes involved in phenotypic sex differentiation,
however it is unclear if these factors are important to gen-
der development. SF-1 and DAX-1 are expressed in the
hypothalamus, and steroid hormone receptors (AR, ER·
and ERß) are located throughout the CNS. Therefore,
these proteins would be the most likely candidates for
influencing gender.
In the case of steroid hormone receptors that are
required to potentiate the activity of male and female hor-
mones, their influence on brain function is probably
entirely related to the action of sex steroids. This hypothe-
sis is supported by patients with complete androgen
insensitivity syndrome and complete gonadal dysgenesis,
where members of both diagnostic groups develop female
GI/R [50].
If male gender development is related to the exposure
of the brain to androgens during fetal life – a hypothesis
that has yet to be proven in humans – then there is no
question about raising 46,XY individuals with a complete
absence of androgen secretion or androgen expression as
females. This includes subjects with complete gonadal
dysgenesis related to abnormalities of the known tran-
scription factors (LIM1, SF-1, WT-1, SRY and SOX-9) as
well as CAIS (AR). Also included are subjects with condi-
tions of complete deficiency of enzymes involved in the
biosynthesis of testosterone from cholesterol.
Mutations resulting in partial deficiency of these gene
products are expected to result in ambiguous external gen-
italia, and possibly partial brain masculinization as well.
In such cases, the dilemma is to decide what is preferable:
a masculinized female or an undermasculinized male. It is
clear that there is no fully satisfactory answer for these
individuals. It would be logical to suggest that minimally
masculinized individuals are more easily raised as fe-
males, whereas markedly masculinized individuals might
be happier if raised as males. However, this leaves a large
group of patients with truly ambiguous genitalia. Such a
situation may support the view that the final decision for
sex of rearing should be left to the patient once that indi-
vidual is prepared to make such a choice. In such cases,
the civil rights of an individual to choose his/her sex
would appear justified [ISNA, www.isna.org].
Unfortunately, delay in assigning the sex of rearing
(gender) of a child presents another question: the parental
viewpoint that it is optimal to assign a sex of rearing as
early as possible. Parents strongly feel that it is their
responsibility to establish a sex of rearing for their child
early in that child’s life. As a corollary, parents also
believe that appropriate reconstructive surgery to mascu-
linize or feminize the external genitalia should be ob-
tained as soon after birth as possible. This feeling is also
shared by many adults born with ambiguous genitalia.
Perhaps a solution is available. With some unusual,
although notable, exceptions, most of our patients accept
their sex of rearing (male or female). Most recognize that
their genital abnormality was, and continues to be, a
major problem coupled with the reality that surgical cor-
rection is never perfect. Despite this, the majority have
achieved a satisfactory quality of life in accordance with
their sex of rearing.
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